Floatz logo

Tak-228

Gliosarcoma

National Cancer Institute (NCI)Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

50 Active assets in the Gliosarcoma cohort.

Asset / SponsorPhaseRating
Cediranib
Northwestern University
Phase 2BBB
Temsirolimus
National Cancer Institute (NCI)
Phase 2BBB
Gefetinib
National Cancer Institute (NCI)
Phase 2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Sorafenib
University Hospital, Geneva
Phase 2BB

View all 50 →

Same molecule, other indications

Tak-228 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Recurrent Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →